Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
PEG-MGF
PEGylated MGF with no identified human exposure data per FDA. Extreme platform risk.
Tier Dextreme risk
02· Subject
CJC-1295
Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.
Tier Bhigh risk
01 · At a glance
| Decision factor | PEG-MGF | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Primary fit | muscle growth & strength research where you want a clear starting point | muscle growth & strength and fat loss & metabolism comparisons | muscle growth & strength and fat loss & metabolism comparisons |
| Evidence | Tier D | Tier B | Tier B-C |
| Risk | extreme | high | high |
| Experience level | advanced | intermediate | intermediate |
| Budget tier | premium | mid | mid |
| Administration route | subcutaneous | subcutaneous | subcutaneous, intravenous |
02 · Use case & timing
| Decision factor | PEG-MGF | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Goal fit | Muscle Growth & Strength | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization |
| What users compare it for | Proposed prolonged muscle repair signaling; claims largely unverified. | Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes). | GH-axis biomarker modulation. Body composition effects are speculative in consumer context. |
| Onset timeline | Unknown in humans. | Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose. | GH pulse effects are acute; body composition claims are long-horizon and not well-established. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | PEG-MGF | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Adverse effects | FDA flags immunogenicity/characterization complexity; no human exposure data identified. | Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses. | Immunogenicity risk (FDA); impurity concerns with unnatural amino acids; glucose/cortisol axis concerns. |
| Contraindications | No data; extreme uncertainty. | GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1. | No established label contraindications (not approved). |
| Interaction notes | Unknown. | Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose. | High uncertainty; glucose/cortisol axis monitoring concerns consistent with secretagogue class. |
| Regulatory status | Not approved | Not approved | Not approved |
| FDA flag | FDA compounding caution | FDA compounding caution | FDA compounding caution |
| WADA status | WADA S2 | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | PEG-MGF | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54 | 25-34, 35-44, 45-54 |
| Life-stage note | Not yet documented | Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited. | Usually framed as a lower-friction GH secretagogue, but age still increases the burden of monitoring and risk review. |
| Monitoring burden | Not specified | high | high |
| Follow-up cadence | Not yet documented | Reassess at startup and then roughly every few months if continuing. | Frequent early review, then periodic reassessment every few months. |
05 · Cost & sourcing
| Decision factor | PEG-MGF | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | $143.98 | $180.00 |
| Estimated monthly cost | No reliable estimate yet | $47.99 | $60.00 |
| Cost confidence | No estimate | High confidence | High confidence |
06 · Before you buy
| Decision factor | PEG-MGF | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | At least one listing is a blend rather than a clean standalone product, so review the product page carefully. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.